Clinical data

Prime Medicine’s Q3 2025 report highlights advancements in its gene editing programs. IND/CTA filing for Wilson’s Disease is expected in H1 2026, with initial data in 2027. PM647 was nominated for AATD, targeting IND/CTA in mid-2026. Preclinical PM577 data will be presented at AASLD. The company reported a $50.6M net loss but holds $227.0M in cash, projected to fund operations into 2027. Matthew Hawryluk was appointed Chief Business Officer. A KOL event on WD strategy is scheduled for November 12, 2025.

Caribou Biosciences (CRBU) will host a webcast on November 3, 2025, to report clinical data from the ANTLER Phase 1 trial of vispa-cel (CB-010) in relapsed/refractory B-NHL and first-time clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The Company will also outline the Phase 3 trial design for vispa-cel and development plans for CB-011. The webcast will be available live and archived on Caribou’s website.